
    
      The goal of this randomized clinical trial (RCT) is to determine vitamin D efficacy and
      safety for improving early markers of T2DM in African American male (AAM) veterans at risk
      for T2DM (n=205, duration 12 months).

      The primary outcome will be change in oral glucose insulin sensitivity (OGIS). The secondary
      outcomes will include various parameters of glucose metabolism and other biomarkers.

      Analysis based on primary and secondary goal as well as predetermined levels of A1C, OGTT and
      25OHD at the end of the study.
    
  